STAT January 6, 2025
Adam Feuerstein

Readouts are coming from Ultragenyx, Akero Therapeutics, and Incyte

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter:

Osteogenesis imperfecta, or OI, is a group of genetic disorders characterized by decreased bone mass and increased bone fragility. Ultragenyx is developing...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Pharma / Biotech
Which Biopharma Startups Made the Cut for INVEST Pitch Perfect?
PBMs push private-label biosimilars in 2025 formularies
CAR T-Cell Pioneer Plots Technology’s Next Steps
Eli Lilly Adds Alzheimer’s Care to Digital Health Platform Services
GLP-1 drug use for weight loss has soared, costing billions

Share This Article